Very hopeful news!
Karmanos Cancer Institute, the largest provider of cancer care and research in Michigan and part of McLaren Health Care, announced that it will be the first provider in the country to offer patients the new FDA-approved TheraBionic P1 device for the treatment of advanced hepatocellular carcinoma (HCC), the most common type of liver cancer. HCC accounts for approximately 90% of all liver cancers, with average survival rates between 6 and 20 months. The innovative TheraBionic P1 device is a novel at-home treatment that emits low levels of radio-frequency electromagnetic fields that block the growth of tumor cells without affecting healthy tissue. The device is approved for treating patients 18 years of age or older who fail first- and second-line therapies. Karmanos’ new president and CEO, Boris Pasche, M.D., Ph.D., FACP,and Anthony Shields, M.D., Ph.D., medical oncologist and leader of the Gastrointestinal and Neuroendocrine Oncology and the Phase 1 Clinical Trials Multidisciplinary Teams, lead the way.
This device potentially could be used to treat pancreatic cancer in the future. Click here to learn more about it.